metoclopramide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sulpiride derivatives 1782 364-62-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metoclopramide
  • metoclopramide hydrochloride
  • metochlopramide
  • methochlopramide
  • metoclopramide hydrochloride hydrate
  • metoclopramide monohydrochloride
  • metoclopramide HCl
  • AHR-3070-C
  • metaclopramide
A dopamine D2 antagonist that is used as an antiemetic.
  • Molecular weight: 299.80
  • Formula: C14H22ClN3O2
  • CLOGP: 2.23
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 67.59
  • ALOGS: -2.99
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P
30 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 33.36 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.20 mg/mL Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 20 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 76 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.60 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 7, 1979 FDA BAXTER HLTHCARE CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1188.22 35.23 364 1722 46279 2309720
Dystonia 400.89 35.23 84 2002 2110 2353889
Tardive dyskinesia 386.04 35.23 78 2008 1626 2354373
Nausea 347.68 35.23 196 1890 111993 2244006
Serotonin syndrome 272.49 35.23 67 2019 3473 2352526
Vomiting 267.09 35.23 142 1944 71460 2284539
Toxicity to various agents 244.72 35.23 105 1981 32649 2323350
Toxic epidermal necrolysis 234.28 35.23 58 2028 3086 2352913
Drug interaction 212.72 35.23 92 1994 29071 2326928
Dyskinesia 205.45 35.23 57 2029 4732 2351267
Restlessness 203.54 35.23 56 2030 4507 2351492
Extrapyramidal disorder 198.69 35.23 48 2038 2299 2353700
Electrocardiogram QT prolonged 186.18 35.23 59 2027 7755 2348244
Drug abuse 180.06 35.23 64 2022 11962 2344037
Seizure 177.60 35.23 77 2009 24389 2331610
Akathisia 171.69 35.23 40 2046 1634 2354365
Tachycardia 171.25 35.23 67 2019 16342 2339657
Exposure during pregnancy 168.87 35.23 75 2011 25144 2330855
Tremor 166.32 35.23 70 2016 20591 2335408
Dyspnoea 162.87 35.23 107 1979 78626 2277373
Parkinsonism 149.24 35.23 35 2051 1470 2354529
Cardiac arrest 148.82 35.23 59 2027 14871 2341128
Anxiety 148.79 35.23 72 2014 29287 2326712
Atelectasis 130.02 35.23 33 2053 1932 2354067
Hypotension 124.64 35.23 66 2020 32370 2323629
Torsade de pointes 120.85 35.23 32 2054 2214 2353785
Fatigue 114.34 35.23 89 1997 84784 2271215
Blister 112.52 35.23 39 2047 6732 2349267
Stevens-Johnson syndrome 104.77 35.23 33 2053 4226 2351773
Electrolyte imbalance 104.73 35.23 28 2058 2009 2353990
Multiple organ dysfunction syndrome 104.17 35.23 38 2048 7603 2348396
Hyponatraemia 103.19 35.23 44 2042 13281 2342718
Asthenia 101.98 35.23 66 2020 46860 2309139
Cardio-respiratory arrest 101.08 35.23 39 2047 9107 2346892
Condition aggravated 100.45 35.23 57 2029 31922 2324077
Movement disorder 100.06 35.23 29 2057 2799 2353200
Neuroleptic malignant syndrome 99.45 35.23 27 2059 2053 2353946
Gastrointestinal disorder 98.45 35.23 38 2048 8879 2347120
Muscle twitching 96.26 35.23 28 2058 2737 2353262
Completed suicide 95.66 35.23 48 2038 20986 2335013
Maternal exposure during pregnancy 95.37 35.23 43 2043 14820 2341179
Confusional state 94.69 35.23 50 2036 24294 2331705
Phaeochromocytoma crisis 94.40 35.23 14 2072 36 2355963
Respiratory disorder 94.23 35.23 30 2056 3974 2352025
Respiratory arrest 92.73 35.23 33 2053 6145 2349854
Computerised tomogram thorax abnormal 90.36 35.23 16 2070 155 2355844
Anaphylactic reaction 88.41 35.23 36 2050 9669 2346330
Diarrhoea 85.90 35.23 75 2011 83489 2272510
Generalised tonic-clonic seizure 85.58 35.23 30 2056 5342 2350657
Hyperhidrosis 84.51 35.23 40 2046 15382 2340617
Decreased appetite 84.00 35.23 49 2037 28842 2327157
Cholecystitis 83.82 35.23 24 2062 2216 2353783
Economic problem 82.97 35.23 17 2069 375 2355624
Hypoxia 81.25 35.23 30 2056 6197 2349802
Hyperthyroidism 80.86 35.23 23 2063 2074 2353925
Agitation 80.61 35.23 35 2051 11016 2344983
Somnolence 79.47 35.23 44 2042 23441 2332558
Dermatitis exfoliative 77.92 35.23 20 2066 1221 2354778
Depression 77.27 35.23 46 2040 28086 2327913
Headache 74.47 35.23 68 2018 80111 2275888
Erythema 73.97 35.23 43 2043 25116 2330883
Hypertension 73.21 35.23 44 2042 27317 2328682
Oculogyric crisis 72.69 35.23 15 2071 343 2355656
Rash 72.49 35.23 59 2027 59499 2296500
Hypokalaemia 72.05 35.23 32 2054 10622 2345377
Alopecia 71.09 35.23 40 2046 21961 2334038
Clonus 70.07 35.23 16 2070 594 2355405
Overdose 69.25 35.23 38 2048 19869 2336130
Impaired gastric emptying 67.94 35.23 17 2069 936 2355063
Nervous system disorder 67.78 35.23 22 2064 3094 2352905
Parkinson's disease 67.06 35.23 18 2068 1308 2354691
Dizziness 66.95 35.23 56 2030 58609 2297390
Poisoning 65.79 35.23 21 2065 2799 2353200
Unresponsive to stimuli 65.47 35.23 24 2062 4852 2351147
Constipation 63.63 35.23 37 2049 21592 2334407
Respiratory syncytial virus infection 63.19 35.23 15 2071 661 2355338
Pyrexia 62.78 35.23 52 2034 53656 2302343
Muscular weakness 61.83 35.23 32 2054 14865 2341134
Cholelithiasis 61.41 35.23 24 2062 5779 2350220
Bradycardia 61.18 35.23 28 2058 9953 2346046
Drug ineffective 60.90 35.23 68 2018 101556 2254443
Loss of personal independence in daily activities 59.87 35.23 23 2063 5288 2350711
Encephalopathy 59.57 35.23 22 2064 4539 2351460
Hypomagnesaemia 59.43 35.23 19 2067 2545 2353454
Speech disorder 58.90 35.23 24 2062 6440 2349559
Chorea 58.58 35.23 12 2074 264 2355735
Phaeochromocytoma 57.81 35.23 11 2075 163 2355836
Loss of consciousness 57.57 35.23 33 2053 18734 2337265
Pruritus 57.04 35.23 45 2041 43295 2312704
Foetal death 56.21 35.23 17 2069 1895 2354104
Methaemoglobinaemia 56.12 35.23 12 2074 327 2355672
Cough 56.06 35.23 40 2046 33077 2322922
Cardiogenic shock 55.85 35.23 18 2068 2473 2353526
Suicide attempt 54.90 35.23 27 2059 11255 2344744
Respiratory failure 53.10 35.23 28 2058 13500 2342499
Hypersensitivity 53.07 35.23 34 2052 23559 2332440
Dysphagia 51.67 35.23 27 2059 12778 2343221
Pain in extremity 51.35 35.23 42 2044 42498 2313501
Skin abrasion 50.94 35.23 14 2072 1111 2354888
Bezoar 49.58 35.23 10 2076 203 2355796
Torticollis 49.56 35.23 11 2075 358 2355641
Myocardial ischaemia 49.30 35.23 16 2070 2246 2353753
Diabetes insipidus 49.30 35.23 11 2075 367 2355632
Intentional overdose 48.92 35.23 25 2061 11296 2344703
Depressed level of consciousness 48.69 35.23 22 2064 7582 2348417
Obstructive airways disorder 48.18 35.23 14 2072 1359 2354640
Hypoglycaemic seizure 47.19 35.23 9 2077 135 2355864
Dry mouth 46.97 35.23 22 2064 8231 2347768
Vascular pain 46.47 35.23 9 2077 147 2355852
Hyperreflexia 44.46 35.23 12 2074 889 2355110
Myoclonus 43.89 35.23 15 2071 2468 2353531
Abdominal pain 43.69 35.23 35 2051 34339 2321660
Muscle spasms 43.40 35.23 29 2057 21537 2334462
Pain 43.25 35.23 45 2041 61812 2294187
Porphyria acute 43.15 35.23 8 2078 102 2355897
Neuropathy peripheral 42.98 35.23 23 2063 11409 2344590
Dysarthria 42.79 35.23 19 2067 6283 2349716
Death 42.76 35.23 51 2035 81417 2274582
Respiratory dyskinesia 42.20 35.23 6 2080 10 2355989
Hepatic failure 41.37 35.23 18 2068 5671 2350328
Infusion site vesicles 41.30 35.23 7 2079 51 2355948
Deformity 41.14 35.23 10 2076 487 2355512
Acute kidney injury 40.86 35.23 31 2055 28091 2327908
Left ventricular dysfunction 40.67 35.23 12 2074 1228 2354771
Muscle rigidity 40.10 35.23 13 2073 1818 2354181
Malaise 39.85 35.23 41 2045 55544 2300455
Chest pain 38.64 35.23 30 2056 28107 2327892
Vitamin B12 decreased 38.56 35.23 9 2077 368 2355631
Off label use 38.47 35.23 46 2040 73552 2282447
Seizure like phenomena 38.46 35.23 8 2078 190 2355809
Ventricular fibrillation 37.75 35.23 13 2073 2188 2353811
Arrhythmia 37.19 35.23 17 2069 6011 2349988
Inappropriate antidiuretic hormone secretion 37.14 35.23 13 2073 2296 2353703
Mental disorder 36.90 35.23 15 2071 3992 2352007
Cogwheel rigidity 36.76 35.23 8 2078 237 2355762
Premature delivery 36.55 35.23 14 2072 3186 2352813
Oxygen saturation decreased 36.42 35.23 18 2068 7568 2348431
Coma 36.24 35.23 19 2067 9037 2346962
Vertigo 35.60 35.23 19 2067 9365 2346634
Back pain 35.53 35.23 30 2056 31629 2324370
Muscle contractions involuntary 35.47 35.23 9 2077 523 2355476
Suicidal ideation 35.31 35.23 20 2066 11067 2344932
Mental status changes 35.25 35.23 16 2070 5566 2350433

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 205.99 37.45 46 968 1968 1743799
Neuroleptic malignant syndrome 195.70 37.45 48 966 3100 1742667
Serotonin syndrome 170.61 37.45 42 972 2746 1743021
Restlessness 138.55 37.45 39 975 4282 1741485
Toxicity to various agents 133.42 37.45 62 952 29079 1716688
Drug hypersensitivity 132.12 37.45 51 963 15084 1730683
Electrocardiogram QT prolonged 120.37 37.45 37 977 5508 1740259
Premature baby 110.07 37.45 30 984 2912 1742855
Tremor 102.98 37.45 41 973 13090 1732677
Tardive dyskinesia 99.65 37.45 23 991 1129 1744638
Drug interaction 99.05 37.45 50 964 27908 1717859
Parkinsonism 95.70 37.45 23 991 1346 1744421
Extrapyramidal disorder 92.43 37.45 25 989 2352 1743415
Vomiting 92.26 37.45 53 961 38262 1707505
Nausea 90.38 37.45 58 956 51138 1694629
Dyskinesia 89.24 37.45 27 987 3792 1741975
Completed suicide 81.46 37.45 37 977 16275 1729492
Cardiac arrest 75.96 37.45 35 979 15895 1729872
Foetal exposure during pregnancy 75.72 37.45 27 987 6332 1739435
Poisoning 72.66 37.45 21 993 2511 1743256
Tachycardia 70.52 37.45 31 983 12597 1733170
Acute kidney injury 70.00 37.45 43 971 34901 1710866
Diarrhoea 66.41 37.45 49 965 53803 1691964
Loss of consciousness 62.58 37.45 30 984 14845 1730922
Muscle rigidity 56.00 37.45 16 998 1832 1743935
Pulmonary interstitial emphysema syndrome 55.57 37.45 8 1006 21 1745746
Agitation 54.89 37.45 25 989 11001 1734766
Hyperhidrosis 51.92 37.45 25 989 12463 1733304
Alveolar lung disease 51.71 37.45 8 1006 39 1745728
Drug dependence 50.68 37.45 17 997 3310 1742457
Confusional state 49.78 37.45 29 985 21249 1724518
Metabolic acidosis 49.72 37.45 19 995 5383 1740384
Anxiety 49.61 37.45 26 988 15501 1730266
Decreased appetite 49.25 37.45 30 984 23841 1721926
General physical health deterioration 47.78 37.45 24 990 13094 1732673
Torsade de pointes 47.10 37.45 13 1001 1311 1744456
Akathisia 47.06 37.45 13 1001 1315 1744452
Tonic convulsion 44.08 37.45 9 1005 245 1745522
Muscle twitching 43.14 37.45 13 1001 1789 1743978
Electrocardiogram QT shortened 42.96 37.45 7 1007 50 1745717
Gastrointestinal hypermotility 42.72 37.45 7 1007 52 1745715
Gait inability 42.70 37.45 15 999 3348 1742419
Dyspnoea 41.91 37.45 37 977 52022 1693745
Hepatocellular injury 39.45 37.45 14 1000 3217 1742550
Asthenia 39.09 37.45 30 984 34640 1711127
Diffuse alveolar damage 37.46 37.45 8 1006 272 1745495

Pharmacologic Action:

SourceCodeDescription
ATC A03FA01 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
PROPULSIVES
Propulsives
FDA MoA N0000175799 Dopamine D2 Antagonists
FDA EPC N0000175800 Dopamine-2 Receptor Antagonist
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:55324 gastrointestinal drug
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D065127 Dopamine D2 Receptor Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetic gastroparesis indication 34140002
Intubation of gastrointestinal tract indication 235419001
Gastroesophageal reflux disease indication 235595009 DOID:8534
Chemotherapy-induced nausea and vomiting indication 236084000
Prevention of Post-Operative Nausea and Vomiting indication
Gastrointestinal Radiography Adjunct indication
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Cirrhosis of liver contraindication 19943007 DOID:5082
Parkinsonism contraindication 32798002
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Mechanical ileus contraindication 46420000
Chronic heart failure contraindication 48447003
Gastrointestinal perforation contraindication 51875005
Gastrointestinal hemorrhage contraindication 74474003
Tardive dyskinesia contraindication 102449007
Deficiency of cytochrome-b>5< reductase contraindication 124184009
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003
Anastomosis of intestine contraindication 235407009
Pheochromocytoma contraindication 302835009
Porphyria contraindication 418470004
Acquired torsion dystonia contraindication 433493000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.17 acidic
pKa2 8.94 Basic
pKa3 1.08 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.19 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 3A Ion channel ANTAGONIST Ki 6.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 4 GPCR AGONIST EC50 6 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.90 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.10 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 4.02 CHEMBL
Aldehyde oxidase Enzyme IC50 4.51 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR WOMBAT-PK
D(3) dopamine receptor GPCR Ki 7.66 WOMBAT-PK
Serotonin 3 (5-HT3) receptor Ion channel Kd 7.30 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.99 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.98 DRUG MATRIX
Serotonin 2 (5-HT2) receptor GPCR IC50 4.88 CHEMBL
Serotonin 3 receptor (5HT3) Ion channel Ki 6.70 CHEMBL
Adrenergic receptor alpha-2 GPCR IC50 5.11 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR IC50 5.11 CHEMBL
D(2) dopamine receptor GPCR Ki 6.98 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 6.68 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 4.48 CHEMBL
D(2) dopamine receptor GPCR Ki 7.10 CHEMBL
D(3) dopamine receptor GPCR IC50 7.21 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.05 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.26 CHEMBL
D(2) dopamine receptor GPCR ANTAGONIST Ki 7.54 IUPHAR
5-hydroxytryptamine receptor 4 Unclassified AGONIST Ki 6 IUPHAR

External reference:

IDSource
4019835 VUID
N0000147923 NUI
C0025853 UMLSCUI
D00726 KEGG_DRUG
56549003 SNOMEDCT_US
4019835 VANDF
6915 RXNORM
372776000 SNOMEDCT_US
d00298 MMSL
004778 NDDF
CHEBI:107736 CHEBI
CHEMBL86 ChEMBL_ID
L4YEB44I46 UNII
1740 INN_ID
54143-57-6 SECONDARY_CAS_RN
DB01233 DRUGBANK_ID
4168 PUBCHEM_CID
CHEMBL1200940 ChEMBL_ID
CHEMBL1256771 ChEMBL_ID
D008787 MESH_DESCRIPTOR_UI
241 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0093-2203 TABLET 10 mg ORAL ANDA 18 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0093-2204 TABLET 5 mg ORAL ANDA 18 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1651 TABLET 10 mg ORAL ANDA 14 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1652 TABLET 5 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0121-0576 SOLUTION 5 mg ORAL ANDA 19 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0121-1576 SOLUTION 5 mg ORAL ANDA 19 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0409-3414 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0440-1771 TABLET 10 mg ORAL ANDA 13 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0615-2536 TABLET 10 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7698 TABLET 5 mg ORAL ANDA 18 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7752 TABLET 10 mg ORAL ANDA 12 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7932 TABLET 10 mg ORAL ANDA 13 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8038 TABLET 10 mg ORAL ANDA 14 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8071 TABLET 10 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8285 TABLET 10 mg ORAL ANDA 18 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 0703-4502 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 13 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 12634-112 TABLET 10 mg ORAL ANDA 13 sections
METOCLOPRAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-150 TABLET 5 mg ORAL ANDA 14 sections
METOCLOPRAMIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-151 TABLET 10 mg ORAL ANDA 14 sections
REGLAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-906 TABLET 10 mg ORAL NDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 17856-0537 SOLUTION 5 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 17856-0576 SOLUTION 5 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 17856-3727 SOLUTION 5 mg ORAL ANDA 14 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 21695-346 TABLET 10 mg ORAL ANDA 11 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 21695-485 TABLET 5 mg ORAL ANDA 11 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 23155-240 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
Metoclopramide HUMAN PRESCRIPTION DRUG LABEL 1 33261-166 TABLET 10 mg ORAL ANDA 13 sections
METOCLOPRAMIDE hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 40032-581 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 17 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42254-196 TABLET 5 mg ORAL ANDA 14 sections
Metoclopramide Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42254-266 TABLET 10 mg ORAL ANDA 14 sections